Evidence map›Paper›PMID 38132177›Full record

ArticleCells2023

Amplification of Signal on Cell Surfaces in Molecular Cascades.

Sergei Rudchenko, Steven Taylor, Nenad Milosavic, Maria Rudchenko, Betina Wedderhoff Tissi, Markus Y Mapara, Milan N Stojanovic

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sergei RudchenkoDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Steven TaylorDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Nenad MilosavicDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Maria RudchenkoDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Betina Wedderhoff TissiDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Markus Y MaparaColumbia Center for Translational Immunology, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Milan N StojanovicDivision of Experimental Therapeutics, Department of Medicine, Columbia University, 630W 168th St., Box 84, New York, NY 10032, USA.
Columbia University · US

Funding

Theranostic Nano-objects: Basic Principles and Initial ApplicationsR01GM104960 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STOJANOVIC, MILAN N, YAN, HAO · 2012 to 2016
$5.4M
Graft Engineering of Allogeneic Hematopoietic Stem Cell Products with Molecular CascadesR01EB025221 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAPARA, MARKUS Y, STOJANOVIC, MILAN N · 2018 to 2021
$2.6M
Theranostic Molecular Automata for Specific Cell EliminationRC2CA147925 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STOJANOVIC, MILAN N · 2009 to 2010
$1.8M
Therapeutic Self-Assembly of Recognition Elements on Cell SurfacesR21CA128452 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STOJANOVIC, MILAN N · 2007 to 2009
$510k
Isolation of narrow subpopulations of cells using molecular computing cascadesR21EB014477 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STOJANOVIC, MILAN N · 2012 to 2013
$463k
NCI NIH HHS R21 CA128452NCI NIH HHS RC2 CA147925NIBIB NIH HHS R01 EB025221NIBIB NIH HHS R21 EB014477NIGMS NIH HHS R01 GM104960
6 · The paper itself

Abstract

We can formulate mixtures of oligonucleotide-antibody conjugates to act as molecular cascade-based automata that analyze pairs of cell surface markers (CD markers) on individual cells in a manner consistent with the implementation of Boolean logic-for example, by producing a fluorescent label only if two markers are present. While traditional methods to characterize cells are based on transducing signals from individual cell surface markers, these cascades can be used to combine into a single signal the presence of two or even more CDs. In our original design, oligonucleotide components irreversibly flowed from one antibody to another, driven by increased hybridizations, leading to the magnitude of the final signal on each cell being determined by the surface marker that was the least abundant. This is a significant limitation to the precise labeling of narrow subpopulations, and, in order to overcome it, we changed our design to accomplish signal amplification to a more abundant cell surface marker. We show the AMPLIFY function on two examples: (1) we amplify the fluorescent label from the CD19 marker onto a fivefold more abundant CD45, and (2) we amplify broadly distributed CD45RA to a more constant marker, CD3. We expect this new function to enable the increasingly complex Boolean analysis of cell surfaces.

Indexed as

Antigens, CD19OligonucleotidesCell MembraneLeukocyte Common AntigensAntigens, CD19Leukocyte Common AntigensOligonucleotidesDNA strand displacement cascadesflow cytometrymolecular programmingnanotechnology

Identifiers

PMID38132177
PMCPMC10742280
OpenAlexW4389883020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.